Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03947970 · ClinicalTrials.gov registry record · Phase 1

Study to Evaluate the Pharmacokinetics and Metabolism of [14C] CR845 (Difelikefalin) in Patients With End Stage Renal Disease on Hemodialysis and in Healthy Subjects

A Phase 1 study of Healthy and Hemodialysis, sponsored by Cara Therapeutics.

Completed
Registry status
Phase 1
Development phase
12
Enrollment target
1
Study location

NCT03947970: Completed Phase 1 study of Healthy and Hemodialysis, sponsored by Cara Therapeutics.

NCT03947970 is a Phase 1 study of Healthy and Hemodialysis that has completed, run by Cara Therapeutics. The registered enrollment target is 12 participants, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03947970, a Phase 1 study of Healthy and Hemodialysis, has completed, sponsored by Cara Therapeutics.

COMPLETED
Registry status
Phase 1
Development phase
12 participants
Enrollment target
1
Study location

Study Summary

The objectives of this study are to evaluate the in vivo metabolite profiling and characterization of CR845 administered intravenously (IV) in patients on hemodialysis (HD) and in healthy subjects; and to determine the pharmacokinetics of radiolabeled \[14C\] CR845 administered as a single IV bolus in patients on HD and in healthy subjects.

Conditions Studied

Interventions

  • DRUG [14C] CR845

Study Locations (1)

Texas

  • Cara Therapeutics Study Site - San Antonio

Trial Details

FieldValue
Enrollment Target 12 participants
Start Date 2019-01-17
Est. Completion 2019-04-06
Phase Phase 1
Cara Therapeutics

23 total trials

What the finished NCT03947970 record still lists

NCT03947970 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 12 participants, a relatively small participant target, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (98% lower).

The record links to 2 conditions, with Healthy appearing as the primary indexed condition, and to 1 intervention - of which [14C] CR845 is the first listed.

NCT03947970 reports a single indexed study location in Texas.

Frequently Asked Questions

What is clinical trial NCT03947970 about?

NCT03947970 is a clinical study titled "Study to Evaluate the Pharmacokinetics and Metabolism of [14C] CR845 (Difelikefalin) in Patients With End Stage Renal Disease on Hemodialysis and in Healthy Subjects". The objectives of this study are to evaluate the in vivo metabolite profiling and characterization of CR845 administered intravenously (IV) in patients on hemodialysis (HD) and in healthy subjects; and to determine the pharmacokinetics of radiolabeled \[14C\] CR845 administered as a single IV bolus ...

What is the current status of trial NCT03947970?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2019-01-17. Estimated completion is 2019-04-06.

What conditions does trial NCT03947970 study?

This clinical trial studies the following conditions: Healthy, Hemodialysis.

What interventions are being tested in trial NCT03947970?

The interventions under investigation include: [14C] CR845 (DRUG).

Who is sponsoring clinical trial NCT03947970?

This trial is sponsored by Cara Therapeutics, which has 23 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03947970 being conducted?

This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Healthy

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT03947970's enrollment target sits among peer trials

12 996th of 1090 higher than 61 of 1,090 other Healthy trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Healthy trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02602769 · 12 participants

    Whole Transcriptome Profiling and Metabolic Phenotyping in Children With ROHHAD Syndrome

  • NCT02605421 · 12 participants · Phase 2

    Myeloablative Consolidation Therapy and Tandem Autologous Stem Cell Rescue in Patients With High-Risk Neuroblastoma

  • NCT02619448 · 12 participants · Early Phase 1

    Concurrent Chemotherapy Plus HFR Radiation Therapy in Inoperable NSCLC

  • NCT03311503 · 12 participants · Phase 1

    Phase I/II Trial of Lentiviral Gene Transfer for SCID-X1 With Low Dose Targeted Busulfan Conditioning

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT03947970, the US trial registry maintained by the National Library of Medicine. NCT03947970 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.